Low-dose factor VIII in adults with haemophilic arthropathy.
27 adults with haemophilic arthropathy infused freeze-dried factor-VIII concentrate at a mean initial dose of 7.3 and 5.5 units/kg, respectively, during two successive 6-month periods of home therapy. A single infusion at either dosage level successfully terminated over 80% of bleeds. A 32% reduction in use of concentrate was achieved at the lower dose, with a cost saving equivalent to pounds 30 000 per annum and with no apparent short-term clinical disadvantage. Thus low-dose therapy can be successfully applied to severely affected adult patients with established haemophilic arthropathy.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D003362:Cost-Benefit Analysis; D005169:Factor VIII / Q000008:administration & dosage*; D005612:Freeze Drying; D006395:Hemarthrosis / Q000209:etiology / Q000628:therapy*; D006467:Hemophilia A / Q000150:complications*; D006699:Home Care Services; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D012646:Self Administration; D013997:Time Factors
D005169:Factor VIII